TL;DR
Senolytic pills aimed at aging's "zombie" cells, the worn-out cells that stop dividing but keep leaking inflammatory signals, poison those cells directly. A Florida company is betting on a different bouncer: the body's own immune system. Immorta Bio says a first patient received its SenoMune-0257 on Oct. 29 in Mexico, a tiny nine-amino-acid peptide designed to teach immune cells to recognize and destroy zombie cells. The hope behind it is a treatment that gets the body to keep its own tissues cleaner as people age, aimed eventually at diseases of the brain, heart and metabolism, scarring diseases, and aging itself. So far it is one advanced-cancer patient and a company announcement, with no data released yet. To see our odds on each step from this first dose to a real trial result, and the timeline of breakthroughs that leads there, subscribe.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.